**Supplement 1: figure 1-6 and table 1-3**

Figure 1. Clinical appearance, laboratory result, and empirical treatment of a hospitalized Melioidosis patient at a tertiary hospital in Yogyakarta, July 2015

**MTZ** 500 mg/ 8 h (21-27 July)

**MEM** 1g/12 h (25-27 July)

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

Leu: 21,030

Leu: 27,500

L1

L2

**AZM** 500mg/12 h (25-27 July)

**CRO** 1g/12h (21-23 July)

Figure 2. Clinical appearance, laboratory result, and empirical treatment of a hospitalized Meliioidosis patient at a tertiary hospital in Yogyakarta,August 2015

**AK** 500mg/12h (27 Aug-16 Sep)

**LVX** 500mg/24h (20-25 Aug)

**AK** 100mg/ 12h (12-27 Aug)

**FCL** 200mg/ 24h (14 Aug-9 Sep)

**GM** 200mg/ 24h (8-12 Aug)

**MTZ** 500mg/8h (8-12 Aug)

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

L7-8

L6

L5

Leu: 23,370

Leu: 20,740

Leu: 21,100

L9

L3

L4

**CAZ** 2g/ 12h (8-12 Aug)

Figure 3. Clinical appearance, laboratory result, and empirical treatment of a hospitalized Meliioidosis patient at a tertiary hospital in Yogyakarta, September 2015

**IPM** 1g/8h (5-22 Sep)

**CFM** 200mg/12h (17- 22 Sep)

**Pelastin** 1g/ 8 h (23 Sep- 6 Oct)

**FCL** 200mg/ 24h (14 Aug-9 Sep)

**AK** 500mg/12h (27 Aug-16 Sep)

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

Leu: 20,530

Leu: 19,650

Leu: 29,400

Leu: 24,700

Figure 4. Clinical appearance, laboratory result, and empirical treatment of a hospitalized Meliioidosis patient at a tertiary hospital in Yogyakarta, October 2015

Pelastin 1g/ 8 h (23 Oct- 5 Nov)

**CL** 2 tab/ 8 h (23 Oct- 31Oct)

**AK** 250mg/12 h (21-22 Oct)

**LVX** 500mg/24h (26 Oct-5 Nov)

Pelastin 1g/ 8 h (23 Sep- 6 Oct)

Leu: 25,270

Leu: 28,520

Leu: 23,860

Leu: 24,420

L10

L11

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

Figure 5. Clinical appearance, laboratory result, and empirical treatment of a hospitalized Meliioidosis patient at a tertiary hospital in Yogyakarta, November 2015

**LVX** 500mg/24h (26 Oct-5 Nov)

**CAZ** 2g/12h (16-17 Nov)

**AN** 500mg/12h (13-15 Nov)

**CTX** 2g/12h (6-19 Nov)

Pelastin 1g/ 8h (23 Oct- 5 Nov)

Leu: 20,590

Leu: 32,390

Leu: 37,970

Leu: 40,550

L15

L14

L13

L12

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

Figure 6. Clinical appearance, laboratory result, antibiotics treatment of a Meliioidosis patient during the hospitalization at ICU of a tertiary hospital in Yogyakarta, December 2019

**MEM** 1g/12h (24 Nov-1 Dec)

**AZM** 500mg/12h (24 Nov-1 Dec)

**AK**: Amikacin, **AZM**: Azithromycin, **CAZ**: Ceftazidime, **CL**: Colistin (Polymyxin E), **CFM**: Cefixime, **CRO**: Ceftriaxone, **CTX**: Cefotaxime, **FLC:** Fluconazole, **GM**: Gentamycin, **IPM**: Imipenem

**MEM**: Meropenem, **MTZ**: Metronidazole, **Pelastin**: Imipenem-Cilastatin, Leu: Leucocyte / μl

Amiodarone, Vascon

Leu: 47,800

Leu: 35,160

Leu: 21,620

Leu: 22,370

Table 1. laboratory result of the melioidosis case on 21 July 2015

|  |  |
| --- | --- |
| Laboratory examination | result |
| Leucocyte | 27,000/ μl |
| Neutrophil | 84.4% |
| Lymphocyte | 7.1% |
| Monocyte | 8.4% |
| Eusinophil | 0 |
| Basophil | 0.1% |
| Thrombocyte | 415,000/ μl |
| Haemoglobin | 7.2 g/dl |
| BUN | 13.4 |
| Creatinine | 1.44 |
| Blood Glucose | 114 g/dl |
| Amilase | 1.76 |
| Lipase 180 | 121 |
| Albumin | 1.68 |
| SGOT | 35 |
| SGPT | 9 |

Table 2. Culture result of a Melioidosis patient during 130 days hospitalization at a tertiary hospital in Yogyakarta (23 July- 2 December 2015)

|  |  |  |  |
| --- | --- | --- | --- |
| **No** | **Date** | **Material** | **Result** |
| L1 | 23 Jul 15 | Blood (2 sites) | Negative |
| L2 | 27 Jul 15 | Blood (2 sites) | Negative |
| L3 | 03 Aug 15 | Pus | Negative |
| L4 | 12 Aug 15 | Pus | Escherichia Coli, ESBL + (contamination) |
| L5 | 12 Aug 15 | Blood (2 sites) | Negative |
| L6 | 16 Aug 15 | Blood (2 sites) | Negative |
| L7 | 24 Aug 15 | Blood (2 sites) | Negative |
| L8 | 25 Aug 15 | Urine | Negative |
| L9 | 29 Aug 15 | Sputum | Streptococci |
| L10 | 12 Oct 15 | Blood (2 sites) | Negative |
| L11 | 27 Oct 15 | Blood (2 sites) | Negative |
| L12 | 03 Nov 15 | Pus | Negative |
| L13 | 11 Nov 15 | Blood (1 sites) | Negative |
| L14 | 15 Nov 15 | Blood (2 sites) | Negative |
| L15 | 20 Nov 15 | Wound swab | 1. *Enterobacter cloacae* 2. *Klebsiella oxytoca* 3. *Burkholderia pseudomallei* 4. *Pseudomonas putida* |

Table 3. Antimicrobial susceptibility of Burkholderia pseudomallei identified from the wound base of the Melioidosis case


|  |  |
| --- | --- |
| **Antibiotics** | **Result** |
| Amikacin | Sensitive |
| Amoxy-Clav | Resistant |
| Ampicillin | Resistant |
| Eritromycin | Resistant |
| Gentamycin | Resistant |
| Levofloxacin | Resistant |
| Chloramphenicol | Resistant |
| Meropenem | Sensitive |
| Penicillin | Resistant |
| Cefepime | Resistant |
| Cefixime | Resistant |
| Ceftriaxone | Resistant |
| Cefuroxime | Resistant |
| Ciprofloxacine | Resistant |
| Sulfametoxazole | Resistant |
| Tetracycline | Not Done |

**Supplement 2: Figure 7-8**

Figure 7. Chest Doppler USG, July, 30, 2019



Figure 8. Abdominal Doppler USG, July, 30 2019



**Supplement 3: Figure 9-10**

Figure 9. Chest X Ray of the melioidosis case taken on Sep, 11th 2015

revealed a pneumonia on both sides of the lung,





Figure 10. MSCT-Scan of the melioidosis case, taken on Aug, 7th 2015, Slide: Splenic Artery(A) Pancreas tail. The MSCT-scan shows pancreas destruction, and adhesion of the intraabdominal organs.



**A**